

Supplementary Table S2. Medications prohibited in the 28 days before start of screening and during the study

-
- Any cytotoxic, immunosuppressive, cytokine-modulating or receptor-antagonist agent
 - Strong CYP1A2 inhibitors (e.g. enoxacin, fluvoxamine); moderate CYP1A2 inhibitors could be administered at pre-specified low doses if the patient was closely monitored for AEs
 - Inhibitors or inducers of P-glycoprotein or CYP3A4
 - Other medications specifically used for treatment of IPF
-

AE, adverse event; CYP1A2, cytochrome P450 1A2; CYP3A4, cytochrome P450 3A4;

IPF, idiopathic pulmonary fibrosis.